Search clinical trials for: (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol

Total 75 results

Lexicon Pharmaceuticals

Completed

Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function

Healthy | Renal Impairment

United States
Sanofi

Completed

Sotagliflozin Bioequivalence Study

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

Healthy

United States
Alessandro Doria
University of Colorado, Denver; University Health Network, Toronto; University... and other collaborators

Not yet recruiting

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease (SUGARNSALT)

Heart Failure | Diabetic Nephropathies | Kidney Failure, Chronic | Diabetes Mellitus Type 1

Canada, United States
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED)

Heart Failure | Chronic Kidney Diseases | Type 2 Diabetes Mellitus

Estonia, Belgium, Sweden, Italy, China, United States, Canada, Bulgaria, Chile, Denmark, Hungary, Latvia, Mexico, Russian Federation, Serbia, Spain, Portugal, Romania, Turkey, Poland, Lithuania, Argentina, Australia, Brazil, Czechia, France, Georg... and more
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Heart Failure | Type 2 Diabetes Mellitus

Belgium, Canada, Israel, Spain, Germany, Argentina, Chile, Hungary, Korea, Republic of, Latvia, Lithuania, Russian Federation, Sweden, Romania, Poland, Brazil, Denmark, United States, Australia, Austria, Czechia, Finland, France, Greece, Ita... and more
Sanofi

Completed

A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions

Type 2 Diabetes Mellitus | Healthy Subjects

United States
Sanofi

Completed

Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

Germany
Lexicon Pharmaceuticals
Sanofi

Completed

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control (SOTA-CKD3)

Type 2 Diabetes Mellitus | Chronic Kidney Disease Stage 3

United States, Argentina, Brazil, Canada, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (inTandem2)

Type 1 Diabetes Mellitus

Israel, Italy, Spain, Bulgaria, Hungary, Poland, Slovakia, United Kingdom, Austria, Belgium, France, Germany, Lithuania, Netherlands, Romania, Sweden, Switzerland
Lexicon Pharmaceuticals
Sanofi

Completed

Dose-ranging Study in Patients With Type 1 Diabetes Mellitus (inTandem4)

Type 1 Diabetes Mellitus

United States
Lexicon Pharmaceuticals
Sanofi

Completed

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone (inTandem3)

Type 1 Diabetes Mellitus (T1DM) | High Level of Sugar (Glucose) in the Blood

United States, Australia, Spain, Belgium, Argentina, Bulgaria, Canada, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, New Zealand, Poland, Slovakia, South Africa, United Kingdom
Lexicon Pharmaceuticals

Completed

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects (AME)

Healthy

United States
Sanofi

Terminated

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise

Type 2 Diabetes Mellitus

China
Sanofi

Completed

Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects

Diabetes Mellitus

China
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Type 2 Diabetes Mellitus

United States, Canada, Mexico
Lexicon Pharmaceuticals
Sanofi

Terminated

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

Cardiac Failure Aggravated

United States, Canada, Netherlands
Lexicon Pharmaceuticals
Sanofi

Completed

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

Healthy | Hepatic Impairment

United States
Lexicon Pharmaceuticals
Sanofi

Terminated

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (SOTA-BONE)

Type 2 Diabetes Mellitus

United States, Australia, Canada, Korea, Republic of, Mexico, New Zealand, Russian Federation, Taiwan
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA-EMPA)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russian Federation, Slovakia, Spain, United Kingdom
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (inTandem1)

Type 1 Diabetes Mellitus

United States, Canada
Lexicon Pharmaceuticals

Completed

Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Steno Diabetes Center Copenhagen
King's College London; Juvenile Diabetes Research Foundation; Glostrup University...

Not yet recruiting

Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia (PLUTO)

Hypoxia | Diabetes Mellitus, Type 1 | Diabetic Nephropathies | Albuminuria | Nephropathy | Diabetic Complications Renal | Diabetic Complications Cardiovascular

Denmark
Juan Badimon

Recruiting

Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients

Heart Failure With Preserved Ejection Fraction

United States
Sanofi

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects

Diabetes Mellitus

United Kingdom
Lexicon Pharmaceuticals
Sanofi

Completed

A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control (SOTA-CKD4)

Type 2 Diabetes Mellitus | Chronic Kidney Disease Stage 4

United States, Argentina, Brazil, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Type 2 Diabetes Mellitus

United States, Canada, Hungary, Slovakia
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Type 2 Diabetes Mellitus | Renal Impairment

United States
Sanofi

Terminated

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Type 2 Diabetes Mellitus

China
Lexicon Pharmaceuticals

Completed

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

Healthy

United States
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Type 2 Diabetes Mellitus

United States, Bulgaria, Estonia, Hungary, Korea, Republic of, Poland, Romania, Slovakia, Ukraine, United Kingdom
University Medical Center Groningen
Juvenile Diabetes Research Foundation; Lexicon Pharmaceuticals

Not yet recruiting

Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation (ASPIRE)

Type 1 Diabetes Mellitus With Diabetic Nephropathy

Netherlands, United States, Canada, Denmark, Finland
University of California, San Diego
Juvenile Diabetes Research Foundation

Not yet recruiting

Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes (SOTA)

Type 1 Diabetes
Lexicon Pharmaceuticals
Sanofi; Juvenile Diabetes Research Foundation

Completed

Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

Type 1 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Diabetes Mellitus

Germany
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Healthy Subjects

United States
Lexicon Pharmaceuticals

Completed

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects

Type 2 Diabetes Mellitus | Healthy Subjects

United Kingdom
Sanofi

Completed

A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril

Diabetes Mellitus | Healthy Subjects

Germany
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy (SOTA-GLIM)

Type 2 Diabetes Mellitus

United States, Bulgaria, Hungary, Slovakia
Sanofi

Completed

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents (SOTA-INS)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Hungary, Slovakia, United Kingdom
Lexicon Pharmaceuticals

Completed

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Unknown

Oral Contraceptive DDI Study

Healthy

United States
Lexicon Pharmaceuticals

Completed

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

Healthy

United States
Lexicon Pharmaceuticals

Completed

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

Healthy

United States
Sanofi

Completed

Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects

Diabetes Mellitus

France

Search clinical trials for: (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations